Prof.Yukio  Nagasaki

Issuing time:2021-09-17 13:08

Name:

Yukio   Nagasaki

Title:

Professor

Affiliation:

University of Tsukuba

Email:

nagasaki@ims.tsukuba.ac.jp

100-word   biography:

Yukio Nagasakiwas born in   1959. He received B.S. and Ph.D. degrees in Engineering School of Science University   of Tokyo in 1982, and 1987. Since 1987, he was working at the Science   University of Tokyo as a Research Associate, Assistant Professor, Associate   Professor, and Professor. In 2004, he moved to Graduate School of Pure and   Applied Sciences, University of Tsukuba. He published more than 200   scientific papers. He received several awards such as The Award of Japanese   Society for Biomaterials (2014), The Nagai Award from The Japan Society of   Drug Delivery System (2015), and Polymer Society award, Japan (2017). He is   now focusing on the development of "self-assembling drugs"   supported by the MEXT budget (Grant #19H05458). We started a nano-particle   type antioxidant, which presents mitochondrial dysfunction of normal cells   and works effectively the oxidative stress-related diseases such as   Alzheimer's disease and cancers. Based on this mechanism, he started to   create a new concept on self-assembling drugs, which can improve their   therapeutic effect and/or decrease their adverse effects, which cannot obtain   by only simple compounds.   Using this   concept, we are now developing versatile drugs based on amino acids and   short-chain fatty acids.

Title:

Novel   drug development based on self-assembly

Abstract:

At the end of the 19th   century, Paul Ehrlich found that methylene blue stains only the nerve endings   of rabbits, so he thought, with a suitable choice of molecules, has no effect   on healthy parts of the body and is influenced to the disease sites. He called   it a "magic bullet" for such drugs. In the 21st century, a   molecular-targeted drug was put into practical use, and his idea was   realized. By the molecular target drugs, have cancer patients disappeared   from the world? The answer is no, in reality, the number of deaths from   cancer patients is steadily increasing year by year. In addition to   developing further effective molecular-targeted drugs, a new concept of   "medicine" is indispensable for reducing patient pain and improving   efficacy. The objective of this research is to construct a new modality for   the development of novel drugs by a new concept of molecular-assembling   medicines following synthetic organic molecules and biomolecular drugs such   as antibody drugs and nucleic acid drugs. This concept is based on the   observation that self-assembling antioxidants suppressed their adverse   effects significantly and accumulate in the inflammation site and effectively   eliminate reactive oxygen species (ROS).   Our results indicate the possibility that biological functions and   therapeutic effects that cannot be obtained with low molecular weight   compounds alone can be controlled by organizing small molecules. In recent   years, in the field of drug discovery and development, several medicines   whose medicinal effects are exerted only by self-assembling have been   discovered. By developing our proposed research, we would like to achieve a   system that is friendly to patients as a basis for the creation of an   innovative drug discovery industry.

Other: